ClinicalTrials.gg
CompletedNCT03308604NANOCOLUpdated Nov 19, 2026

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

A Phase 1 interventional study of Polysiloxane Gd-Chelates based nanoparticles (AGuIX) and External beam radiotherapy (EBRT) in Gynecologic Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Completed at 2 sites in France. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method.

Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).

02

Conditions studied

  • Gynecologic Cancer
03

In context

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed cancer of the uterine cervix: squamous cell carcinoma or adenocarcinoma stage IB2-IVA according to the International Federation of Gynecology and Obstetrics classification, regardless of the pelvic lymph node stage. No evidence of disease. Primary staging should include: clinical examination, Pelvic MRI and 18-FDG PET. A coelioscopic para-aortic lymph node staging should be done in patients without para-aortic lymph node uptake to guide radiotherapy fields in the situation of pelvic lymph node metastases. If there is no pelvic lymph node metastases, para-aortic lymph node dissection is optional.
  2. performance status 0-1.
  3. Age between 18 - 70 years.
  4. Neutrophils > 2000/mm\^3.
  5. > 9 g/L after transfusion if necessary.
  6. > 100,000/mm\^3.
  7. Creatinine \< 1.5 or calculated (Cockcroft-Gault Formula) ≥ 60 mL/min.
  8. Liver function (GOT, GPT, alkaline phosphatase and ) \< 1.5 upper limit of normal.
  9. Cardiovascular: no cardiovascular disease, no congestive heart failure, no symptomatic coronary artery disease, no poorly controlled cardiac arrhythmia, no myocardial infarction within the past year.
  10. Gastrointestinal: no active inflammatory bowel disease, no lack of physical integrity of the upper gastrointestinal tract, no malabsorption syndrome.
  11. Women of must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
  12. Proteinuria \< 2 g/L (200mg/dL) and creatinine clearance ≥ 60 mL/min.
  13. Signed after informing the patient.
  14. Patient affiliated to a social security regimen or beneficiary of the same.

Exclusion criteria

Exclusion Criteria:

  1. Other histological types of cervical cancer than those listed in the inclusion criteria or stage IVB.
  2. History of cancer other than basal cell carcinoma within five past years.
  3. Prior treatment with radiotherapy, chemotherapy, targeted therapy or immune therapy for cervical cancer or for any cancer within five past years.
  4. Prior pelvic radiotherapy or prior surgical treatment for cervical cancer (excluding diagnostic conisation).
  5. Pregnancy or breastfeeding.
  6. Obesity ( > 30).
  7. History of prior or current psychiatric illness.
  8. Nephropathy, regardless of the grade.
  9. Peripheral neuropathy ≥ grade 2.
  10. Patients with pre-existing hearing impairments.
  11. Active infection or other serious underlying pathology that could prevent the patient from receiving the treatment (especially liver or heart conditions).
  12. Positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
  13. Positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  14. Inclusion in another clinical trial protocol with an experimental molecule (during this study or within 5 years prior to enrollment).
  15. Unable to undergo the follow-up required by study for geographical, social or psychological reasons.
  16. for Magnetic Resonance Imaging enhanced with gadolinium and/or any contra-indication to the use of cisplatin.
  17. History of allergic reaction to cisplatin or other platinum containing compounds.
  18. Concurrent administration of yellow fever vaccine.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Patients with locally advanced cervical cancer

    Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX) · Radiation: External beam radiotherapy (EBRT) · Radiation: Uterovaginal brachytherapy · Drug: Chemotherapy (cisplatin)

Interventions

  • DrugAGuIXStudies of AGuIXAGuIX pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three intravenous injections of AGuIX will be delivered. The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake. Irradiation will be performed after the second MRI. The second injection will be followed by an MRI 4 hours later. The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance. Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg.

  • RadiationExternal beam radiotherapy (EBRT)

    to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases

  • RadiationUterovaginal brachytherapy

    15 Gy (maximal interval between EBRT and brachytherapy: 14 days).

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Time frame: Day 84 after inclusion

  2. Recommended Phase 2 Dose (RP2D)

    Time frame: Day 84 after inclusion

07

Study locations

2 sites
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhône 69310, France
  • Gustave Roussy
    Villejuif, Val de Marne 94800, France
08

References and documents

Publications

  • Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Bockel S, Genestie C, Wu TD, Lux F, Tillement O, Lacombe S, Deutsch E, Robert C, Porcel E. Clinical transfer of AGuIX(R)-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework. Nanomedicine. 2023 Jun;50:102676. doi: 10.1016/j.nano.2023.102676. Epub 2023 Apr 20. PubMed 37084803 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2018 to primary completion in Jul 2022, 50 months.

Completion moved once since we started tracking on Sep 25, 2026: May 2024 → Nov 2022, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2017
First posted
Oct 12, 2017
StartActual
May 17, 2018
Primary completionActual
Jul 25, 2022
CompletionActual
Nov 25, 2022was May 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Gustave Roussy · Villejuif, France
Show 1 removed
  • Gustave Roussy · Villejuif, France
Nov 19, 2026
Study completion
May 2024→Nov 25, 2022 (actual)
Nov 19, 2026
Enrollment
18 (estimated)→12 (actual)
Nov 19, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37084803 ↗
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37084803 ↗
    1 site added, 1 site removed
    Show site
    • Gustave Roussy · Villejuif, France
    Show 1 removed
    • Gustave Roussy · Villejuif, France
    Study completion May 2024→Nov 25, 2022 (now actual)
    Enrollment 18 (estimated)→12 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03308604
Collaborators
National Cancer Institute, France
Responsible party
Sponsor
First posted
Oct 12, 2017
Start date
May 17, 2018
Primary completion
Jul 25, 2022
Completion
Nov 25, 2022
Last update
Nov 19, 2026

Study contacts

Cyrus CHARGARI, MD
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGuIX

Start the discussion